Elsevier

Pathology

Volume 50, Issue 3, April 2018, Pages 257-260
Pathology

Editorial
Antifungal susceptibility testing in Australasian clinical laboratories: we must improve our performance

https://doi.org/10.1016/j.pathol.2018.01.001Get rights and content

Section snippets

Conflicts of interest and sources of funding

The authors state that there are no conflicts of interest to disclose.

References (14)

There are more references available in the full text version of this article.

Cited by (6)

  • Evaluation of a custom Sensititre YeastOne plate for susceptibility testing of isavuconazole and other antifungals against clinically relevant yeast and mould species in three Australian diagnostic mycology laboratories

    2022, Pathology
    Citation Excerpt :

    Both reference methodologies allow reproducible and reliable in vitro susceptibility data to be generated, which is essential for the development of interpretive criteria. However, for both methodologies, in-house preparation of the plates is labour-intensive, requires extensive quality control, and plates must be stored at –70oC (≤6 months) which challenges their routine use.8 Instead, many diagnostic laboratories rely on commercial AFST methods, in particular the Sensititre YeastOne (SYO) microdilution plate (ThermoFisher Scientific, USA).

  • Antifungal susceptibility of clinical mould isolates in New Zealand, 2001–2019

    2021, Pathology
    Citation Excerpt :

    While not currently used locally for mould susceptibility testing this is likely to change, as it has recently for bacterial susceptibility testing. However, there are important method differences between CLSI and EUCAST and results generated by one method must not be interpreted with criteria used by the other.31 Lastly, we have not had any molecular testing performed for acquired mechanisms of azole resistance.

  • Antifungal Susceptibility Testing and Identification

    2021, Infectious Disease Clinics of North America
    Citation Excerpt :

    Siopi and colleagues75 compared SYO color end points with the requisite MEC end points of CLSI M38-A2, noting that the SYO end points were up to three 2-fold dilutions lower than the CLSI method. However, they did not compare the MEC end points of the 2 methods by determining the point whereby filamentous hyphal growth changes to granular compact hyphal balls, ignoring the broth color, as we have previously recommended.47 Inoculum preparation, incubation time, and the end point reading of SYO with molds (ie, growth reduction/effect as opposed to color change) should be guided by CLSI M38.41

  • Updating of in vitro antifungal susceptibility tests

    2019, Enfermedades Infecciosas y Microbiologia Clinica
  • Disseminated Rasamsonia argillacea infection in a dog

    2023, New Zealand Veterinary Journal
View full text